Akebia Broadens Scope with Rare Kidney Disease Program Led by AKB-097, Praliciguat
Akebia shifts beyond anemia into rare kidney diseases with a pipeline anchored by AKB-097 and praliciguat, signaling strategic diversification and new clinical priorities.
Yahoo Finance
2 min read
Stocks
Biotech
Healthcare